MARKSANSPharmaceuticals
Marksans Pharma Ltd — Profit & Loss Statement
₹156.89
-1.28%
Marksans Pharma Ltd Profit & Loss Statement (Annual)
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Tax Effect Of Unusual Items | -1.80 Cr | 0.34 Cr | -5.45 Cr | 0.76 Cr | — |
| Tax Rate For Calcs | 0.24 | 0.26 | 0.21 | 0.25 | — |
| Normalized EBITDA | 606.47 Cr | 507.69 Cr | 420.68 Cr | 294.57 Cr | — |
| Total Unusual Items | -7.46 Cr | 1.31 Cr | -25.43 Cr | 3.11 Cr | — |
| Total Unusual Items Excluding Goodwill | -7.46 Cr | 1.31 Cr | -25.43 Cr | 3.11 Cr | — |
| Net Income From Continuing Operation Net Minority Interest | 380.57 Cr | 313.70 Cr | 266.31 Cr | 184.57 Cr | — |
| Reconciled Depreciation | 83.39 Cr | 74.27 Cr | 51.85 Cr | 44.78 Cr | — |
| Reconciled Cost Of Revenue | 1.23K Cr | 1.10K Cr | 958.08 Cr | 716.82 Cr | — |
| EBITDA | 599.01 Cr | 509.00 Cr | 395.25 Cr | 297.68 Cr | — |
| EBIT | 515.63 Cr | 434.73 Cr | 343.40 Cr | 252.90 Cr | — |
| Net Interest Income | 18.54 Cr | 22.58 Cr | 2.91 Cr | -2.47 Cr | — |
| Interest Expense | 11.66 Cr | 11.20 Cr | 5.75 Cr | 5.39 Cr | — |
| Interest Income | 30.20 Cr | 33.79 Cr | 12.04 Cr | 5.97 Cr | — |
| Normalized Income | 386.24 Cr | 312.73 Cr | 286.29 Cr | 182.22 Cr | — |
| Net Income From Continuing And Discontinued Operation | 380.57 Cr | 313.70 Cr | 266.31 Cr | 184.57 Cr | — |
| Total Expenses | 2.16K Cr | 1.79K Cr | 1.54K Cr | 1.26K Cr | — |
| Rent Expense Supplemental | 11.73 Cr | 12.24 Cr | 12.91 Cr | 4.74 Cr | — |
| Diluted Average Shares | 45.32 Cr | 45.32 Cr | 41.54 Cr | 40.93 Cr | — |
| Basic Average Shares | 45.32 Cr | 45.32 Cr | 41.54 Cr | 40.93 Cr | — |
| Diluted EPS | 8.40 | 6.92 | 6.41 | 4.51 | — |
| Basic EPS | 8.40 | 6.92 | 6.41 | 4.51 | — |
| Diluted NI Availto Com Stockholders | 380.57 Cr | 313.70 Cr | 266.31 Cr | 184.57 Cr | — |
| Net Income Common Stockholders | 380.57 Cr | 313.70 Cr | 266.31 Cr | 184.57 Cr | — |
| Otherunder Preferred Stock Dividend | 0.00 | 0.00 | 0.00 | 0.00 | — |
| Net Income | 380.57 Cr | 313.70 Cr | 266.31 Cr | 184.57 Cr | — |
| Minority Interests | -2.04 Cr | -1.20 Cr | 0.99 Cr | -2.25 Cr | — |
| Net Income Including Noncontrolling Interests | 382.62 Cr | 314.89 Cr | 265.32 Cr | 186.81 Cr | — |
| Net Income Continuous Operations | 382.62 Cr | 314.89 Cr | 265.32 Cr | 186.81 Cr | — |
| Tax Provision | 121.35 Cr | 108.63 Cr | 72.33 Cr | 60.70 Cr | — |
| Pretax Income | 503.97 Cr | 423.53 Cr | 337.65 Cr | 247.51 Cr | — |
| Other Non Operating Income Expenses | 13.81 Cr | 3.90 Cr | 7.49 Cr | 9.56 Cr | — |
| Special Income Charges | -4.15 Cr | -3.06 Cr | -14.63 Cr | -2.52 Cr | — |
| Other Special Charges | -2.24 Cr | -0.13 Cr | 0.26 Cr | -0.12 Cr | — |
| Write Off | 6.39 Cr | 3.19 Cr | 14.36 Cr | 2.63 Cr | — |
| Net Non Operating Interest Income Expense | 18.54 Cr | 22.58 Cr | 2.91 Cr | -2.47 Cr | — |
| Interest Expense Non Operating | 11.66 Cr | 11.20 Cr | 5.75 Cr | 5.39 Cr | — |
| Interest Income Non Operating | 30.20 Cr | 33.79 Cr | 12.04 Cr | 5.97 Cr | — |
| Operating Income | 455.72 Cr | 387.50 Cr | 312.90 Cr | 216.74 Cr | — |
| Operating Expense | 929.27 Cr | 689.75 Cr | 578.64 Cr | 546.57 Cr | — |
| Other Operating Expenses | 211.06 Cr | 167.40 Cr | 127.18 Cr | 153.27 Cr | — |
| Depreciation And Amortization In Income Statement | 83.39 Cr | 74.27 Cr | 51.85 Cr | 44.78 Cr | — |
| Amortization | 11.22 Cr | 12.30 Cr | 10.48 Cr | 4.09 Cr | — |
| Depreciation Income Statement | 72.17 Cr | 61.97 Cr | 41.37 Cr | 40.69 Cr | — |
| Selling General And Administration | 281.20 Cr | 145.40 Cr | 149.84 Cr | 134.20 Cr | — |
| Selling And Marketing Expense | 256.64 Cr | 127.31 Cr | 133.19 Cr | 119.05 Cr | — |
| General And Administrative Expense | 24.57 Cr | 18.09 Cr | 16.66 Cr | 15.15 Cr | — |
| Rent And Landing Fees | 11.73 Cr | 12.24 Cr | 12.91 Cr | 4.74 Cr | — |
| Gross Profit | 1.38K Cr | 1.08K Cr | 891.54 Cr | 763.31 Cr | — |
| Cost Of Revenue | 1.23K Cr | 1.10K Cr | 958.08 Cr | 716.82 Cr | — |
| Total Revenue | 2.61K Cr | 2.17K Cr | 1.85K Cr | 1.48K Cr | — |
| Operating Revenue | 2.61K Cr | 2.17K Cr | 1.85K Cr | 1.48K Cr | — |
| Total Other Finance Cost | — | — | 3.38 Cr | 3.06 Cr | 4.52 Cr |
All figures in ₹ Crores. Source: NSE/BSE filings via Bull Run.
More on Marksans Pharma Ltd
Data from NSE/BSE public filings. Educational purposes only. Bull Run is not SEBI-registered. Not investment advice.